Holen Sie sich die Stockscreener-App
4.56
8.06%
-0.40
Schlusskurs vom Vortag:
$4.96
Offen:
$4.91
24-Stunden-Volumen:
278.57K
Relative Volume:
0.62
Marktkapitalisierung:
$34.98M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-73.52M
KGV:
-6.9091
EPS:
-0.66
Netto-Cashflow:
$-100.45M
1W Leistung:
-15.24%
1M Leistung:
-3.39%
6M Leistung:
-53.85%
1J Leistung:
-60.10%
1-Tages-Spanne:
$4.55
$5.00
1-Wochen-Bereich:
$4.55
$5.545
52-Wochen-Spanne:
$3.61
$19.43
Precision Biosciences Inc Stock (DTIL) Company Profile
Firmenname
Precision Biosciences Inc
Sektor
Branche
Telefon
919-314-5512
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Vergleichen Sie DTIL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.56 | 34.98M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Eingeleitet | Guggenheim | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-09 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Stifel | Buy |
| 2020-02-25 | Eingeleitet | William Blair | Outperform |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
| 2019-04-22 | Eingeleitet | Goldman | Buy |
| 2019-04-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-04-22 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
Precision BioSciences (DTIL) Poised for Growth with ARCUS Technology and Strategic Partnerships - HPBL
Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL
Geode Capital Management LLC Raises Holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) - Defense World
Precision BioSciences (NASDAQ:DTIL) Earns “Buy” Rating from HC Wainwright - Defense World
Precision BioSciences (NASDAQ:DTIL) Raised to “Outperform” at BMO Capital Markets - Defense World
BMO Capital Upgrades Precision BioSciences (DTIL) - MSN
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst - Benzinga
Precision BioSciences Shares Surge 60% After Breakthrough Clinical Results for OTC Deficiency Treatment - HPBL
Precision Bio stock upgraded at BMO (update) (DTIL:NASDAQ) - Seeking Alpha
Precision BioSciences upgraded to Outperform at BMO on favorable risk/reward - Investing.com Canada
Pre-Market Surge For Precision BioSciences (DTIL) On Groundbreaking Trial Data - Stocks Telegraph
Precision BioSciences shares soar on promising gene editing trial results By Investing.com - Investing.com Australia
Precision BioSciences shares soar on promising gene editing trial results - Investing.com
Head-To-Head Review: Allogene Therapeutics (NASDAQ:ALLO) versus Precision BioSciences (NASDAQ:DTIL) - Defense World
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency - BioSpace
DTILPrecision BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) invests $10M in Alamar Biosciences, Inc. to Advance Precision Medicine in Alzheimer’s Disease - The Scientist
Precision BioSciences Gene Therapy Shows Breakthrough Success in Infant OTC Deficiency Trial - StockTitan
Precision BioSciences projects extended cash runway into 2026 - Investing.com
Precision Biosciences director Germano purchases $16,186 in stock By Investing.com - Investing.com Canada
Insider Buying: Geno Germano Acquires Shares in Precision BioSci - GuruFocus.com
Precision Biosciences director Germano purchases $16,186 in stock - Investing.com
Precision BioSciences stock hits 52-week low at $4.12 By Investing.com - Investing.com Canada
Precision Biosciences director Kevin Buehler buys $21,081 in stock By Investing.com - Investing.com Nigeria
Precision BioSciences stock hits 52-week low at $4.12 - Investing.com India
Precision Biosciences CFO buys $10,036 in common stock By Investing.com - Investing.com Canada
Insider Buying: Kevin Buehler Acquires Shares of Precision BioSc - GuruFocus.com
Insider Buying: John Kelly Acquires Shares of Precision BioScien - GuruFocus.com
Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):